ClinicalTrials.gg
CompletedNCT01995383Updated Nov 4, 2016

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

A Phase 1 interventional study of LS followed by NS diet condition and NS followed by LS diet condition in Atherosclerosis, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Enrollment
178th of 328
88 · median 119
Started
2013
with 10 others
Phase 1
38 of 468
1 open now
Registered
262nd of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 178th largest by enrollment of the 328 interventional ones that give a count, is one of 11 that started in 2013, is one of 38 in phase 1, and was the 262nd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

This single-center, randomized, placebo-controlled, double-blind study will assess the safety, pharmacokinetics and pharmacodynamics of RO6836191 in healthy male volunteers in two parts. Part 1 will assess the safety of oral single ascending doses of RO6836191 compared to placebo in fasted volunteers. In Part 2, participants will be given two single oral doses of RO6836191 or placebo under low or normal-salt diet conditions. A subset of these participants will subsequently receive a single IV dose of RO6836191 for further analysis.

03

Conditions studied

  • Atherosclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers, aged 18 to 45 years old.
  • No active or chronic disease following a detailed medical and surgical history and complete physical examination.
  • A between 18 to 30 kg/m2 inclusive.
  • Use of a highly effective form of for the duration of the study and until 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Any current or history of conditions or illnesses.
  • Clinically significant symptoms of infection within 5 days of the first dosing day or a history of recurrent infections.
  • Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse.
  • Smokers unable or unwilling to restrict to 5 cigarettes daily during the study and to not smoke during the stay at the clinic.
  • Any cardiac abnormalities.
  • Blood donation over 450 mL within three months prior to screening.
  • Participation in an drug or device study within 3 months prior to dosing.
  • use within 3 months prior to dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo (PL)

    Drug: Placebo

  • Experimental
    Part 1: Single Ascending Doses (SAD) of RO6836191

    Drug: RO6836191

  • Placebo comparator
    Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet

    Other: LS followed by NS diet condition · Drug: Placebo · Drug: RO6836191

  • Placebo comparator
    Part 2: PL: NS followed by LS diet

    Other: NS followed by LS diet condition · Drug: Placebo · Drug: RO6836191

  • Experimental
    Part 2: RO6836191: LS followed by NS diet

    Other: LS followed by NS diet condition · Drug: RO6836191

  • Experimental
    Part 2: RO6836191: NS followed by LS diet

    Other: NS followed by LS diet condition · Drug: RO6836191

Interventions

  • OtherLS followed by NS diet condition

    LS diet period followed by NS diet period

  • OtherNS followed by LS diet condition

    NS diet period followed by LS diet period

  • DrugPlacebo

    Single oral administrations

  • DrugPlacebo

    2 single oral administrations

  • Orally administered, single ascending doses

  • 2 single oral doses

  • Intravenous administration

06

What researchers measure

Primary outcomes

  1. Part 2: Area under the concentration-time curve (AUC)

    Time frame: Up to Day 35

  2. Part 2: Plasma aldosterone levels

    Time frame: Up to 2 days after drug administration

  3. Part 2: Urine aldosterone levels

    Time frame: Up to 3 days after drug administration

  4. Part 1: Plasma aldosterone levels

    Time frame: Up to Day 5

  5. Part 1: Urine aldosterone levels

    Time frame: Up to Day 3

  6. Part 2: Incidence of AEs

    Time frame: Up to 12 weeks

  7. Parts 1: Incidence of adverse events (AE)

    Time frame: Until Day 21

Secondary outcomes

  1. Part 2: Volume of distribution after intravenous administration

    Time frame: Days 28-37

07

Study locations

1 site
  • Marlton, New Jersey 08053, United States
08

References and documents

Publications

  • Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, De Vera Mudry MC, Brown MJ, Ferber P. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 2017 Jan;69(1):189-196. doi: 10.1161/HYPERTENSIONAHA.116.07716. Epub 2016 Nov 21. PubMed 27872236 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2013
First posted
Nov 26, 2013
Start
Nov 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01995383
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Nov 2013
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Nov 4, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion